Axsome Therapeutics, Inc. (0HKF.L)
USD 101.16
(-6.16%)
USD 101.16
(-6.16%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 397.25 Million USD | 79.01% |
| 2022 | 221.91 Million USD | 213.26% |
| 2021 | 70.84 Million USD | -2.07% |
| 2020 | 72.34 Million USD | 72.95% |
| 2019 | 41.82 Million USD | 189.64% |
| 2018 | 14.44 Million USD | -23.34% |
| 2017 | 18.83 Million USD | 13.2% |
| 2016 | 16.64 Million USD | 532.29% |
| 2015 | 2.63 Million USD | -56.05% |
| 2014 | 5.98 Million USD | 45.18% |
| 2013 | 4.12 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 445.37 Million USD | 10.87% |
| 2024 Q1 | 401.69 Million USD | 1.12% |
| 2023 Q2 | 332.83 Million USD | 20.0% |
| 2023 Q1 | 277.36 Million USD | 24.99% |
| 2023 FY | 397.25 Million USD | 79.01% |
| 2023 Q4 | 397.25 Million USD | 19.89% |
| 2023 Q3 | 331.34 Million USD | -0.45% |
| 2022 Q2 | 165.35 Million USD | 123.88% |
| 2022 Q4 | 221.91 Million USD | 22.2% |
| 2022 Q1 | 73.86 Million USD | 4.26% |
| 2022 FY | 221.91 Million USD | 213.26% |
| 2022 Q3 | 181.59 Million USD | 9.82% |
| 2021 Q2 | 71.82 Million USD | 1.72% |
| 2021 Q4 | 70.84 Million USD | -4.11% |
| 2021 FY | 70.84 Million USD | -2.07% |
| 2021 Q3 | 73.88 Million USD | 2.86% |
| 2021 Q1 | 70.61 Million USD | -2.39% |
| 2020 FY | 72.34 Million USD | 72.95% |
| 2020 Q1 | 41.64 Million USD | -0.44% |
| 2020 Q2 | 36.74 Million USD | -11.76% |
| 2020 Q3 | 68.36 Million USD | 86.05% |
| 2020 Q4 | 72.34 Million USD | 5.81% |
| 2019 Q3 | 37.61 Million USD | 23.36% |
| 2019 Q1 | 26.52 Million USD | 83.69% |
| 2019 FY | 41.82 Million USD | 189.64% |
| 2019 Q2 | 30.49 Million USD | 14.96% |
| 2019 Q4 | 41.82 Million USD | 11.19% |
| 2018 Q3 | 15.38 Million USD | 4.53% |
| 2018 Q1 | 15.35 Million USD | -18.5% |
| 2018 FY | 14.44 Million USD | -23.34% |
| 2018 Q4 | 14.44 Million USD | -6.12% |
| 2018 Q2 | 14.71 Million USD | -4.15% |
| 2017 Q1 | 17.13 Million USD | 2.94% |
| 2017 FY | 18.83 Million USD | 13.2% |
| 2017 Q4 | 18.83 Million USD | 19.39% |
| 2017 Q3 | 15.77 Million USD | -3.13% |
| 2017 Q2 | 16.28 Million USD | -4.92% |
| 2016 Q1 | 3.91 Million USD | 48.7% |
| 2016 FY | 16.64 Million USD | 532.29% |
| 2016 Q4 | 16.64 Million USD | 147.07% |
| 2016 Q3 | 6.73 Million USD | 31.98% |
| 2016 Q2 | 5.1 Million USD | 30.4% |
| 2015 FY | 2.63 Million USD | -56.05% |
| 2015 Q2 | 14.08 Million USD | 0.0% |
| 2015 Q4 | 2.63 Million USD | 17.81% |
| 2015 Q3 | 2.23 Million USD | -84.14% |
| 2015 Q1 | - USD | -100.0% |
| 2014 FY | 5.98 Million USD | 45.18% |
| 2014 Q4 | 5.98 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | 4.12 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 36.339% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -215.037% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 35.688% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -50.059% |
| bluebird bio, Inc. | 424.62 Million USD | 6.445% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -477.756% |
| Imunon, Inc. | 8.53 Million USD | -4556.965% |
| Editas Medicine, Inc. | 150.05 Million USD | -164.74% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 98.069% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 88.668% |
| Myriad Genetics, Inc. | 312.9 Million USD | -26.96% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 61.03% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 18.504% |
| Verastem, Inc. | 71.18 Million USD | -458.066% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.423% |
| Waters Corporation | 3.47 Billion USD | 88.573% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.234% |
| Biogen Inc. | 12.04 Billion USD | 96.702% |
| Nektar Therapeutics | 267.04 Million USD | -48.761% |
| Perrigo Company plc | 6.04 Billion USD | 93.424% |
| Dynavax Technologies Corporation | 375.02 Million USD | -5.929% |
| Illumina, Inc. | 4.36 Billion USD | 90.901% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1029.311% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -102.954% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -54.889% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -965.266% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 78.982% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -381.917% |
| Evolus, Inc. | 209.68 Million USD | -89.453% |
| Adicet Bio, Inc. | 37.12 Million USD | -970.202% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -887.568% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 94.41% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 39.881% |
| FibroGen, Inc. | 585.72 Million USD | 32.177% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 91.922% |
| OPKO Health, Inc. | 622.47 Million USD | 36.181% |
| Homology Medicines, Inc. | 118.53 Million USD | -235.146% |
| Geron Corporation | 146.12 Million USD | -171.859% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 90.192% |
| Exelixis, Inc. | 678.44 Million USD | 41.446% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1879.269% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -3069.451% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -58.392% |
| Zoetis Inc. | 9.29 Billion USD | 95.726% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -707.831% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 92.286% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -720.021% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 84.741% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 83.484% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -246.008% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 75.916% |
| Blueprint Medicines Corporation | 918.64 Million USD | 56.756% |
| Insmed Incorporated | 1.66 Billion USD | 76.094% |
| TG Therapeutics, Inc. | 169.08 Million USD | -134.946% |
| Incyte Corporation | 1.59 Billion USD | 75.051% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 66.493% |